Anaesthesia Management and Use of Sugammadex in a Patient with Ullrich’s Disease
PDF
Cite
Share
Request
Case Report
P: 356-359
October 2015

Anaesthesia Management and Use of Sugammadex in a Patient with Ullrich’s Disease

Turk J Anaesthesiol Reanim 2015;43(5):356-359
1. Department of Anaesthesiology and Reanimation, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
2. Department of Paediatric Surgery, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
No information available.
No information available
Received Date: 04.09.2014
Accepted Date: 18.11.2014
Publish Date: 21.08.2015
PDF
Cite
Share
Request

ABSTRACT

Here, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich’s disease. Propofol and remifentanyl infusion was used for anaesthesia. After the end of the surgery, when the train-of-four value was 0%, 4 mg kg−1 sugammadex was administered, and the patient was successfully extubated after 36 s. No adverse effects or safety concerns were observed. In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.

Keywords: Sugammadex, muscular dystrophy, total intravenous anaesthesia

References

2024 ©️ Galenos Publishing House